EUVIMEDEUVIMED entdecken
Crossref

Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy

Yihong He, Yan Ju, Yuzhu Hu, Bilan Wang, Siyao Che, Yue Jian, Weiling Zhuo, Xianghui Fu, Yongzhong Cheng, Songping Zheng, Ning Huang, Zhiyong Qian und 3 weitere

Journal of Controlled Release · 2023-02 · 354 · 155-166

DOI: 10.1016/j.jconrel.2022.12.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-02. Verfasst von Yihong He und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China; Department…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Nanoparticles. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Sichuan Province Science and Technology Support Program, National Natural Science Foundation of China, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bromodomain-Containing Protein 4 (BRD4) is a member of the BET family of bromodomains, which participates in gene transcription process and is closely related to tumor progression. We observed the up-regulated expression of BRD4 in colorectal cancer (CRC) after doxorubicin (DOX) treatment, which might be a potential mechanism for DOX resistance. This study constructed the tumor-targeting (cyclo (Arg-Gly-Asp-D-Phe-Lys)-poly(ethylene glycol)-poly(ε-caprolactone)) (cRGD-PEG-PCL) copolymer for co-delivery of DOX and BRD4 PROTAC degrader ARV-825 (ARV-DOX/cRGD-P) for CRC treatment. The ARV-DOX/cRGD-P complexes elicited synergistic anti-tumor effect via cell cycle arrest and the increased cell apoptosis, and mechanism studies implicated the regulation of proliferation- and apoptosis-related pathways in vitro. Moreover, the administration of ARV-DOX/cRGD-P significantly improved anti-tumor activity in subcutaneous colorectal tumors and colorectal intraperitoneal disseminated tumor models in mice by promoting tumor apoptosis, suppressing tumor proliferation and angiogenesis. Taken together, these data reveal that ARV-825 can heighten DOX sensitivity in CRC treatment and BRD4 is a potential therapeutic target for DOX-resistant CRC. The ARV-DOX/cRGD-P preparations have outstanding anti-cancer effects and may be used for clinical treatment of colorectal cancer in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNanoparticlesAnimalsMiceNuclear ProteinsCell Line, TumorProteolysis Targeting ChimeraProteolysisTranscription FactorsDoxorubicinAntibiotics, AntineoplasticAzepinesThalidomide

Stichwörter der Autor:innen

BRD4 PROTAC degrader ARV-825Colorectal cancerCombination therapyNanoparticlesResistance

Substanzen

Nuclear ProteinsProteolysis Targeting ChimeraTranscription FactorsDoxorubicinAntibiotics, AntineoplasticARV-825AzepinesThalidomide

Autor:innen und Institutionen

  • Department of Pathophysiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China; Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory o…
  • Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for…
  • Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 6100…
  • Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu 610041, China.
  • Department of Pathophysiology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China. Electronic address: huangpangxiao2012@163.com.

Förderung

  • Sichuan Province Science and Technology Support Program
  • National Natural Science Foundation of China
  • Sichuan University
  • West China Hospital, Sichuan University

Zitieren

APA

He, Y., Ju, Y., Hu, Y., Wang, B., Che, S., Jian, Y., Zhuo, W., Fu, X., Cheng, Y., Zheng, S., Huang, N., Qian, Z., Liu, J., Zhou, P., & Gao, X. (2023). Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. Journal of Controlled Release, 354, 155-166. https://doi.org/10.1016/j.jconrel.2022.12.035

Vancouver

He Y, Ju Y, Hu Y, Wang B, Che S, Jian Y, et al. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. Journal of Controlled Release. 2023;354:155-166. doi:10.1016/j.jconrel.2022.12.035

BibTeX
@article{He2023,
  author = {He, Yihong and Ju, Yan and Hu, Yuzhu and Wang, Bilan and Che, Siyao and Jian, Yue and Zhuo, Weiling and Fu, Xianghui and Cheng, Yongzhong and Zheng, Songping and Huang, Ning and Qian, Zhiyong and Liu, Jiagang and Zhou, Peizhi and Gao, Xiang},
  title = {Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {354},
  pages = {155--166},
  doi = {10.1016/j.jconrel.2022.12.035}
}
Kostenlos starten →